CorMedix Inc. (CRMD)
NASDAQ: CRMD · Real-Time Price · USD
9.10
-0.05 (-0.55%)
Apr 25, 2025, 4:00 PM EDT - Market closed
CorMedix Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for CorMedix stock have an average target of 14.5, with a low estimate of 12 and a high estimate of 18. The average target predicts an increase of 59.34% from the current stock price of 9.10.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CorMedix stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 4 | 4 | 4 |
| Buy | 2 | 2 | 2 | 2 | 3 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 6 | 6 | 7 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +31.87% | Apr 9, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $15 | Strong Buy | Maintains | $15 | +64.84% | Apr 8, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $12 | Buy | Reiterates | $12 | +31.87% | Mar 26, 2025 |
| Needham | Needham | Strong Buy Maintains $18 → $12 | Strong Buy | Maintains | $18 → $12 | +31.87% | Mar 26, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $15 | Strong Buy | Maintains | $15 | +64.84% | Mar 25, 2025 |
Financial Forecast
Revenue This Year
133.74M
from 43.47M
Increased by 207.65%
Revenue Next Year
200.78M
from 133.74M
Increased by 50.13%
EPS This Year
0.69
from -0.30
EPS Next Year
1.54
from 0.69
Increased by 121.90%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 152.4M | 261.5M | 341.5M | ||
| Avg | 133.7M | 200.8M | 268.1M | ||
| Low | 122.7M | 146.4M | 138.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 250.5% | 95.5% | 70.1% | ||
| Avg | 207.6% | 50.1% | 33.5% | ||
| Low | 182.2% | 9.5% | -31.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.98 | 2.32 | 3.29 | ||
| Avg | 0.69 | 1.54 | 2.23 | ||
| Low | 0.52 | 0.77 | 0.79 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 234.1% | 113.2% | ||
| Avg | - | 121.9% | 44.5% | ||
| Low | - | 11.5% | -48.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.